Uveitis is the most common form of intraocular inflammatory disease and is a significant cause of visual impairment worldwide. Aetiologically, uveitis can also be classified into infectious uveitis and non-infectious uveitis. The common non-infectious forms of uveitis include acute anterior uveitis (AAU), Behçet’s disease (BD), Vogt-Koyanagi-Harada (VKH) disease, birdshot chorioretinopathy (BSCR), sarcoid uveitis. In addition, a few monogenic autoinflammatory disorders can also cause uveitis, such as Blau Syndrome and haploinsufficiency of A20 (HA20). Although the exact pathogenesis of non-infectious uveitis is still unclear, it is well-recognised that it involves both genetic and environmental risk factors. A hallmark of uveitis is its strong associations with human leucocyte antigens (HLA). For examples, AAU, BD and BSCR are strongly associated with HLA-B27, HLA-B51, and HLA-A29, respectively. In uveitis studies, multiple GWAS have successfully been conducted and led to identification of novel susceptibility loci, for example, IL23R has been identified in BD, VKH and AAU. In this review, we summarize the latest progress on the genetic associations of both HLA and non-HLA genes with major forms of uveitis, including AAU, BD, VKH, BSCR, sarcoid uveitis, Blau Syndrome and HA20, and potential future research directions.

Genes & Immunity (2022) 23:57–65; https://doi.org/10.1038/s41435-022-00168-6

INTRODUCTION

Uveitis is the most common form of intraocular inflammatory disease, leading to 5–10% of visual impairment worldwide [1]. Uveitis can be anatomically classified into anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. In addition, according to aetiological factors, uveitis can also be classified into infectious uveitis and non-infectious uveitis. Of the two categories, non-infectious uveitis is the most commonly seen and important type, and includes acute anterior uveitis (AAU), Behçet’s disease (BD), and Vogt-Koyanagi-Harada (VKH) disease [2]. Although the exact pathogenesis is still unclear in many forms of uveitis, it is well-recognised that non-infectious uveitis involves both genetic predisposition and environmental risk factors [3].

Strong associations of human leucocyte antigens (HLA) with different forms of uveitis have been identified since the early 1970s [4]. With advances in sequencing and genotyping methodology, genetic studies have enhanced our understanding of the disease aetiology. Over the past decade, genome-wide association study (GWAS) in particular has proven to be a powerful and robust method to identify genetic associations with complex diseases, particularly immune-mediated diseases [5]. The discoveries of novel associations between genomic variants and diseases not only has provided new insights into biological pathways [5], but can also lead to clinical translational applications in diagnosis, prevention, and treatment. This review will summarize the latest progress on the genetic associations of HLA and non-HLA genes with major forms of uveitis, including AAU, BD, VKH, birdshot chorioretinopathy, sarcoid uveitis, and Blau Syndrome.

ACUTE ANTERIOR UVEITIS

Acute anterior uveitis (AAU) is the most common type of uveitis, characterized by episodic, typically unilateral, sudden-onset, inflammation of the iris and/or ciliary body. Its clinical presentations encompass pain, eye redness, photophobia, and blurred vision, associated with cellular infiltration and fibrin formation in the anterior chamber (AC). Episodes last a mean of 6–8 weeks [6]. Recurrent episodes can lead to synechiae formation, glaucoma, and visual impairment/loss. AAU is frequently associated with spondyloarthropathies, such as ankylosing spondylitis (AS), psoriatic arthritis, and inflammatory bowel disease [7]. For example, Wang et al. investigated a total of 202 patients presenting with AAU who underwent clinical and radiographic (CT) screening for sacroiliitis, and found that 80 (39.6%) had AS [8].

Multiple lines of evidence from humans indicate that genetic components play a critical role in AAU. Derhaag et al. found that the prevalence of AAU in HLA-B27-positive first-degree relatives of AAU patients was 13%, significantly higher than the frequency of 1% in the HLA-B27-positive individuals without affected relatives, indicating high familiality [9]. Recently, our group’s GWAS for AAU demonstrates that AAU is a highly heritably disorder [10]. The contribution of common genetic variants to overall disease risk (‘common variant heritability’) was ~0.4 in the comparison between AS patients with AAU and AS patients without AAU [10]. Interestingly, in the comparison between AS patients with AAU and controls, the estimated heritability reached 0.7 [10].

AAU is strongly associated with human leucocyte antigen (HLA)-B27. The association between HLA-B27 and AAU was originally reported in 1973 and remains one of the strongest human
HLA-disease associations [4]. The prevalence of HLA-B27 among AAU patients reaches 80% [8], whereas it is only ~6% in general populations [11]. In 2015, Robinson et al. reported the prevalence of HLA-B27 was 81.8% (613 of 749 patients) in the group with AS and ophthalmologist-diagnosed AAU and 92.0% (633 of 688 patients) in the group with AS and self-reported AAU [12]. Another larger genetic study reported the frequency of HLA-B27 in the AS patients with AAU was 92.7% (1307/1409), and the prevalence was 76.4% (1296/1695) in the cohort of AS patients without AAU [13]. A recent analysis of British patients receiving biologic medications for AS found that 23.5% of patients reported AAU, and that HLA-B27 was associated with an increased risk of AAU complicating AS (HLA-B27 carriage in overall cohort 80.1%, in those with AS and AAU, 88.7%) [14].

Whilst the strongest genetic association of AAU is with HLA-B27, there is strong evidence for the involvement of other HLA alleles with AAU. The development of methods by which HLA alleles can be accurately imputed from SNP microarray data has greatly facilitated this research, providing a low cost and highly accurate HLA typing method enabling large sample sizes to be studied, and at the same time, for variation in ethnicity (‘population stratification’) to be assessed and controlled for. Using the Illumina Immunochip Infinium microarray [15], Robinson et al. conducted genetic analysis between AAU and healthy control subjects found significant association over HLA-B, corresponding to the HLA-B27 tag SNP rs116488202 [12]. Further analysis showed that HLA-B27 homozygotes were at increased risk compared with heterozygotes (odds ratio 1.8, 95% CI 1.3–2.2). Another study conducted by comparing AS patients with AAU versus healthy controls demonstrates that HLA-B27 and HLA-A*0201 were strongly associated with AAU using Illumina Exomechip microarray [15]. A large direct genotyping study confirmed the association of HLA-B27 with an increased risk of AAU amongst AS patients, including in African ancestry patients, and suggested a protective association of HLA-B*08 for AAU amongst AS cases (odds ratio 0.48, P = 10^{-10}) [16]. Whether these non-HLA-B alleles are directly associated with AS or reflect association of other major histocompatibility complex genes is unclear at this point.

In addition to HLA-B, SNP microarray studies have reported the association of 3 non-MHC loci with genome-wide significance (P < 5 x 10^{-8}), including ERAP1, IL23R and one intergenic region (2p15). Suggestive level of significance (P < 5 x 10^{-6}) was also been observed with SNPs in five additional loci, including IL10-IL19, IL18R1-IL1R1, IL6R, 1q32, and a retinal-related gene EVS [12]. Candidate-gene association studies have reported nominal SNP associations in Interleukins (ILs) genes and tumour necrosis factor (TNF) genes correlated with anterior uveitis [17–19]. Another key component is the complement system, which is also involved in innate immunity and inflammatory responses. Genetic associations of complement factor H (CFH), complement factor B (CFB), complement factor I (CFI) and complement factor H related 2 (CFHR2) have been reported [8, 20–23]. Notably, CFB localizes to the MHC class III region. These complement genes and the TNF gene are in strong linkage disequilibrium with HLA-B27, and their association is likely to have been substantially if not completely driven by HLA-B27 carriage differences between cases and controls. As with most candidate gene association studies, the analysis for these studies did not control for potential population stratification effects either, and thus differences in the ethnic makeup of cases and controls studied could have affected the results.

Recently, our group applied GWAS to characterise the genetic associations of AAU, on the basis of comparing 2752 AS patients with AAU versus 3,836 AS patients without AAU. This study identified one locus associated with AAU at genome-wide significance, rs9378248, lying close to HLA-B. HLA imputation demonstrated HLA-B*27 (P = 1.86 x 10^{-25}) was the most significantly associated allele with AAU. Suggestive association (P > 5 x 10^{-8} but < 1 x 10^{-5}) was observed at eleven additional loci, including previously reported AS loci ERAP1 (rs27529 and NO52 (rs2724894)). In addition to these discoveries, association was seen at loci not previously known to be associated with AAU or AS, including MER7K, KIFAP3, CLCN7, ACA2A and five intergenic loci [10]. The summary data-based Mendelian randomization (SMR) for AAU with eQTL was performed to determine the most likely causal genes at associated loci. Interestingly, the most significant signals were ERAP1 and MERTK. These findings suggest that ERAP1 and MERTK are the most functionally relevant genes among those loci [10].

Our analysis for the first time showed that genome-wide polygenic risk scores (PRS) have strong power in identifying individuals at high risk of either AS with AAU or AS alone. In the comparison of patients with AS with AAU (AS + AAU+) versus controls, genome-wide PRS has higher discriminatory capacity (AUC = 0.96) than computing PRS using HLA-B27 alone (AUC = 0.92) [10]. Assuming the prevalence of AAU+ cases is 0.3% among the general population, individuals in the top 10% of genetic risk had an estimated genetic risk of developing AS with AAU of 10.1%, and those in the bottom 85% had <0.1% chance of developing the disease (Fig. 1) [10]. Considering the situation in outpatient clinics and assuming the prevalence is 20%, those in the top 10% and top 5% of genetic risk had an estimated genetic risk of developing disease of 90.3% for 93.2%, respectively (Fig. 1) [10]. Similar results were also reported in PRS study of AS cases. In individuals of European descent, PRS had better discriminatory capacity (AUC = 0.924) better than for HLA-B27 testing alone (AUC = 0.869) or MRI (AUC = 0.885) [24]. Assuming a prior probability for AS of 30% in clinical practice, Li et al reported the PRS PPV is >80.6% for top 35% of AS cases, showing a higher maximum value (93.3%) than does HLA-B27 (80.6%) (Fig. 2). The PRS NPV is >92.4% for 65% of cases, with a higher maximum value (99.6%) than does HLA-B27 (92.4%) (Fig. 2). These findings suggested that PRS could assist clinical diagnosis.

A key challenge in these studies is distinguishing associations of AAU as opposed to of AS. This has largely been achieved using AS cases who do not yet have AAU as controls. This model though has two significant weaknesses. Firstly, whilst it is effective at identifying AAU associations over and above any association the locus may have with AS, it cannot identify associations of AAU where the association has similar strength to any association the locus may have with AS. In that setting, no association is seen in the comparison of AS with AAU compared with AS without AAU, despite the locus being associated with AAU. To identify such associations, GWAS of AAU cases that lack concomitant AS will be required. Secondly, as many of the AS cases without AAU will ultimately develop AAU, inevitably some misclassification occurs, resulting in loss of power. Again, this issue could be resolved by the study of AAU cases not affected by AS in comparison with healthy controls.

**BEHçET’S DISEASE**

Behçet’s disease (BD) is a chronic multisystemic inflammatory disorder characterized by recurrent uveitis, oral aphthae, arthritis, genital ulcers, and skin inflammation. BD exists worldwide but has an ethnic predominance in countries along the ancient Silk Routes spanning from Asia to the Mediterranean basin, including China, Japan, Korea, and Turkey. Multiple genetic studies have provided evidence that genetic risk factors contribute to disease susceptibility. HLA-B*51 is the most strongly associated risk factor for BD, which was identified more than four decades ago and has been confirmed in multiple ethnic populations [25, 26]. With the exception of the strong association in the HLA region, multiple candidate gene association studies and GWAS have discovered non-HLA susceptibility loci and genes for BD. Herein, we review the progress of GWAS for BD thus far.
The first preliminary GWAS for BD was conducted in 2009, but this study was limited by mapping resolution and low detection power [27]. In 2010, two groups identified novel loci associated with BD by GWAS. Remmers et al. conducted a GWAS in 1,215 cases and 1,278 healthy controls from Turkey. They confirmed the association of BD with HLA-B*51 and identified associations at IL10, IL23R-IL12RB2 and CPLX1 [28]. At the same time, another group reported similar findings in different population. Mizuki et al. performed a GWAS in Japanese and also identified significant associations with SNPs in IL23R-IL12RB2 and IL10 [29]. Crucially, for the first time, these studies revealed significant SNPs associations in non-MHC regions. The first GWAS in Chinese population was conducted in 2012. Although the case sample size was small (149 cases and 951 controls in the discovery study), this study reported an association with SNPs in STAT4 at genome-wide significance, and functional studies indicated its role in disease pathogenesis through the up-regulation of IL-17 production [30]. This association was intriguing, as STAT4 is part of the signalling...
pathway from IL-12 rather than IL-23. It is known that IL-17-inhibition with secukinumab is not effective in BD uveitis [31], and indeed cases of BD developing as an apparent complication of secukinumab treatment have been reported [32]. This, and the association of STAT4 with the disease, suggests that IL-12 and the Th1 pathway is more important in driving BD than is the IL-23 Th17 pathway. Subsequently, Kirino et al. performed imputation using previously genotyped data, and identified new susceptibility loci at CCR1, STAT4, KLRC4 and ERAP1 [33]. Additionally, this study discovered the evidence for interaction between HLA-B*51 and ERAP1 [33]. This is of particular interest given the known interaction between HLA-B27 and ERAP1 variants in AS [34], and between HLA-Cw6 and ERAP1 variants in psoriasis [35]. In each case the interaction suggests that variations in antigenic peptide handling and processing by ERAP genes and HLA-B are involved in the disease pathogenesis. This study also demonstrated near genome-wide significant association of IL12A with BD, again consistent with the hypothesis that this is a Th1 driven disease.

Another group conducted a GWAS for BD in Korean population. This study found a significant association with SNPs in GIMAP gene cluster, which is involved in T-cell survival, but failed to replicate the association of the IL23R-IL12RB2 and IL10 loci [36]. In 2017, Takeuchi et al. using the immunogenetically targeted SNP microarray Illuminomo studied the largest BD discovery collection thus far, comprising 1900 cases and 1,779 controls [37]. This study identified several new susceptibility loci reached genome-wide significance, IL1A-IL1B, ADO-EGR2, CEBPB-PTPN1, IRF8, LACC1, and RIPK2. A few loci previously reported for BD were also replicated, including HLA-B*51, CCR1, ERAP1, FUT2, IL10, IL12A, IL23R-IL12RB2, and KLRC4 [37]. Pathway analysis showed these genes were involved in host defence, inflammation, and immune response. Moreover, this study increased the number of susceptibility loci known to be shared by BD and inflammatory bowel disease (IBD). Comparing among subgroups of IBD, Takeuchi et al. found higher genetic similarity of BD with Crohn’s disease than with ulcerative colitis [37].

GWAS is a powerful methodology to identify common variants associated with inflammatory diseases, but not suited for investigating the roles of rare or low-frequency variants with little or no surrounding linkage disequilibrium. Kirino et al. performed targeted resequencing of 21 genes, including 10 genes discovered by GWAS and 11 genes selected for their role in innate immunity, to compare the distribution of nonsynonymous variants with MAF <1% in BD patients and healthy controls. This study using burden testing demonstrated suggestive association of IL23R and TL1A4 with BD, and demonstrated that the M694V MEFV polymorphism, which causes the autoimmune inflammatory disease Familial Mediterranean Fever, is associated with BD [38].

Vogt-Koyanagi-Harada Disease

Vogt-Koyanagi-Harada (VKH) disease is a multisystemic autoimmune disorder characterized by bilateral panuveitis as well as neurosensory (septic meningitis), auditory (loss, vertigo, tinnitus), and dermatological (vitiiligo, poliosis, alopecia areata) manifestations. VKH disease is one of the most common forms of uveitis in Asians, and is also prevalent in North Africans, Hispanics, and some natives of South America, whereas it is uncommon in Caucasians [39]. Gender differences have been observed in most studies, with females being likely to be affected than males, although this was no gender bias was observed in east Asian studies [40]. Although the exact pathogenesis of AAU remains unclear, recent genetic studies have enhanced our understanding of the disease aetiology. This review summarizes the main findings of genes associated with VKH disease.

The first strong association between HLA and VKH disease was discovered in 1981, namely HLA-DR4 and HLA-Dw53 [41]. The finding was since then confirmed in different ethnic populations. In addition to HLA-DR4 and HLA-Dw53, in certain populations, other HLA-antigens were also identified to be associated with VKH disease, such as HLA-DR1, HLA-DQw7, and HLA-DQ4 [42-44]. With advances in genotyping methodology, HLA can be defined not only by serologic typing, but also at the DNA level. Strong association of HLA-DQA1*0301, HLA-DQB1*0604, HLA-DRB1*0405 and HLA-DQB1*0401 with VKH disease have been observed in East Asian [43, 45, 46]. In contrast, HLA-DRB1*0404, DRB1*0102 and DRB1*0410 were associated with VKH disease in mestizo patients in Southern California [47], suggesting association of different HLA-antigens or alleles with VKH disease depending on the ethnic population. The complexity and magnitude of linkage disequilibrium across the MHC, and modest size of these studies has to date precluded definitive identification of the associated alleles.

In addition, various other non-HLA genes have also been shown to be associated at nominal levels of significance with VKH disease by candidate gene association studies. These studies focused on the association of certain important functional genes involved in either innate or adaptive immune response. These genes are related to Killer immunoglobulin-like receptors (KIR), complement components, pattern recognition receptors, cytokines, chemokines, transcription factors, cell activation and inhibition, apoptosis. The first GWAS for VKH, involving 744 Chinese cases and 2,009 healthy controls [48]. This study identified two new susceptibility loci associated with VKH disease reached genome-wide significance, IL23R-C1orf141 (rs117633859) and ADO-ZNF365-EG2 (rs442309), in a family of interest that these associations are shared by uveitis associated with both BD and AAU. These findings have recently been replicated in a Japanese case-control candidate gene association study [49]. Hou et al. also demonstrated association between HLA genes and VKH disease, showing the strongest association with SNP at HLA-DRB1/DQA1 locus (rs3021304).

Birdshot Chorioretinopathy

Birdshot chorioretinopathy (BSCR) is a chronic, bilateral, autoimmune posterior uveitis typically affecting middle aged and elderly individuals of Caucasian origin. BSCR manifests as a severe progressive intraocular inflammation of the posterior eye segment, including vitritis, retinal vascular leakage, and cream-coloured spots at the level of the retinal pigment epithelium (RPE) or deeper retinal layers. As the spots scattered throughout the fundus that appear like birdshot from a shotgun, the first use of the term “birdshot chorioretinopathy” was introduced by Ryan and Maumenee in 1981 [50]. Unlike AAU, BD and VKH, birdshot chorioretinopathy is an uncommon form of uveitis, and is generally considered to be an isolated ocular disorder [51]. Although the strong association of BSCR and HLA-29 has been well recognised, the immunogenetic mechanisms of BSCR is still unclear, especially the genetic basis of BSCR. Here we summarize current knowledge in genetics of the disease, including the genetic association with HLA-A29 allele.

The association of HLA-A29 with BSCR was first reported almost four decades ago [52]. The prevalence of HLA-A29 in patients with BSCR is over 95% and the relative risk for developing disease in HLA-A29 positive individuals has been estimated to be as high as 224 [53]. Of note, about 7% of the Caucasian population is HLA-A29 positive, so HLA-A29 is supportive of diagnosis, but not essential for diagnosis [54]. Consistently, the lack or low incidence of BSCR in certain Asian populations may be attributable to the low prevalence of the HLA-A29 allele [55]. HLA-A29 can be divided into more than 20 subtypes, but the most common subtypes in Caucasian population are HLA-A*2901 and HLA-A*2902, which have both been observed to have a strong association with BSCR [56]. HLA-A*2901 and HLA-A*2902 differ only by a single mutation (G376C/D102H), hence this does not appear to affect peptide binding
In addition, another much rarer allele, HLA-A*29:10, has also been incidentally reported in BSCR patients [59]. Although it was to elucidate the roles of non-HLA genes, especially the ERAP1 flu, IntraSarcoid Uveitis and ERAP2 with sarcoidosis [68, 69]. Moreover, GWAS and candidate gene studies have found that short tandem repeats near HLA-A*29:02 locus at 5q15 (rs7705093) near three members of the M1 family of aminopeptidases (ERAP1, ERAP2 and LNPEP) and at 14q32.31 (rs150571175) in the TECPR2 gene [60]. The ERAP1/ERAP2 locus at chromosome 5q15 has strong linkage disequilibrium across it, and has variants with both strong effects on expression as well as on protein-coding and splice variation [61], making it challenging to determine primary associations. The authors then performed eQTL analysis to explore the biological relevance of the association at 5q15, and found the strongest impact was on ERAP2 expression, suggesting ERAP2 is the causal gene at this locus [60]. Functional analysis of ERAP2 protein expression and an independent replication study further confirmed the association of ERAP2 with BSCR, suggesting a novel disease mechanism that affects peptide processing in the endoplasmic reticulum [60]. Recently, Sanz-Bravo et al. performed label-free quantitative mass spectrometry to characterize the effects of ERAP2 on the A*29:02-bound peptidome, which supported that the association of ERAP2 with BSCR is through its effects on peptide processing [62]. Of note, Alvarez-Navarro et al. conducted a study to investigate the influence of ERAP1 polymorphism on the amounts and features of HLA-A*29:02 ligands in human cells. The resulted showed that ERAP1 polymorphism has a large influence, shaping the HLA-A*29:02 peptidome [63]. Future research on BSCR genetics with a larger sample size are needed to elucidate the roles of non-HLA genes, especially the ERAP1, ERAP2 and LNPEP genes.

**Sarcoid Uveitis**

Sarcoidosis is a multi-system chronic inflammatory disease of unknown aetiology characterized by the formation of non-caseating granulomas in affected organs, most commonly the lungs, skin, lymphatics, and eyes. Sarcoidosis is one of the leading causes of inflammatory ocular disorder. The prevalence of ocular involvement in different ethnic population ranges from 12.9% (Turkish) to 79.2% (Japanese) of patients with sarcoidosis [64, 65]. Uveitis is the most frequent form of ocular manifestation and may affect up to 20–50% of sarcoidosis patients [66]. To date, multiple studies have demonstrated that genetic factors play an important role in sarcoidosis. Strong heritability has been demonstrated, with a study of twins from Denmark and Norway estimating heritability of sarcoidosis to be 66% [67]. HLA class II antigens, HLA-DRB1, and HLA-DQB1, have been identified to be associated with sarcoidosis [68, 69]. Moreover, GWAS and candidate gene studies have identified a few susceptibility loci for sarcoidosis, such as BTLN2, NOTCH4, RAB23, and ANXA17 [70–72].

In contrast with these findings on overall sarcoidosis, there are few studies that have specifically investigated the association between genetic variants and sarcoid uveitis, with no GWAS yet published for sarcoid uveitis. Candidate gene studies have largely examined the associations between the known genes of overall sarcoidosis and sarcoid uveitis, mostly showing no significant differences in patients with sarcoid uveitis [73, 74]. Davoudi et al. identified SNPs in two sarcoid-related genes, RAB23 and ANXA11, which were associated with an increased risk of sarcoid uveitis based on the comparison of sarcoid uveitis versus sarcoid without uveitis [75]. Thompson et al. found that CFH Y402H polymorphism (rs1061170) was associated with sarcoid uveitis by comparing cases versus sarcoidosis-free controls [76]. CFH is known to be strongly associated with age-related macular degeneration. Other associations have been identified with SNPs in HSPA1L (also known as HSP70-HOM), IL23R, and IL10, although these have only been at nominal levels of significance [77–79]. Although these studies are all based on small sample size and lacking independent replication, the findings suggest the shared aetiology in sarcoid uveitis and other forms of uveitis. Future studies are necessary to reveal both specific associations and associations shared with overall sarcoidosis and other types of uveitis.

**Monogenic Autoinflammatory Disorders with Uveitis**

In addition to polygenic autoinflammatory diseases, a few monogenic autoinflammatory disorders can also cause uveitis. Herein, we introduce the genetic findings of Blau Syndrome and haploinsufficiency of A20.

**Blau Syndrome**

Blau Syndrome (BS) is a rare monogenic autoinflammatory disease characterized by recurrent non-caseating granulomatous symmetric arthritis, dermatitis, and uveitis. In 1985, BS was firstly reported by Dr Blau, describing a dominant pedigree with paediatric onset of granulomatous uveitis, arthritis, and dermatitis [80]. BS is caused by mutations in the NOD2 gene (also named CARD15), encoding nucleotide binding oligomerization domain containing 2, with autosomal dominant inheritance pattern [81]. NOD2 variants are associated with Crohn’s disease [82], and to a lesser extent with AS, psoriasis and ulcerative colitis [83]. Mutations in NOD2 can also lead to early-onset sarcoidosis (EOS) [84]. Because of the striking clinical similarities and genetic background between BS and EOS, some researchers proposed that BS and EOS are the familial and sporadic forms, respectively, of the same disease [85]. On the other hand, some authors suggested to classify these patients as sporadic BS caused by de novo mutations in NOD2 gene, using the term EOS to those patients without NOD2 mutations [86]. Currently, more authors proposed that BS and EOS are the same non-caseating granulomatous inflammatory disease, respectively defined as the familial and sporadic forms [87, 88]. Although the prevalence and incidence of BS still remains unclear, more than 200 cases of BS have been reported worldwide by 2017 in the literature [89]. Reported mutations are mainly located in the NACHT domain, and might decrease the threshold for spontaneous oligomerization of NOD2. Among those NOD2 mutations, R334W and R334Q are the most frequent mutations, suggesting codon 334 as a genetic hot spot for mutations [90]. Due to the complexity of clinical manifestations of BS, genetic analysis can significantly assist early diagnosis and treatment.

**Haploinsufficiency of A20**

Haploinsufficiency of A20 (HA20) is a monogenic autoinflammatory disease with phenotypes resembling BD, caused by heterozygous mutations in TNFAIP3 gene, which encodes the NF-kB regulatory protein A20. In 2016, HA20 was firstly reported by Zhou and colleagues, describing six unrelated families with early-onset...
systemic inflammation [91]. Using whole-exome sequencing and targeted sequencing, Zhou et al. identified three nonsense mutations and three frameshift mutations in TINF2 gene [91]. Since then, patients with HA20 were reported in different populations.

Because of the clinical similarities with BD, the majority of patients (>70%) were initially diagnosed or suspected of having BD [92]. Thus, it is of importance to recognise clinical characteristics that can assist to differentiate HA20 from BD. By comparison of clinical features between HA20 and BD, recent studies revealed a few specific features of HA20, including early-onset, autosomal dominant pedigree, recurrent fever, gastrointestinal involvement, and isolated anterior uveitis or retinal vasculitis [92–94]. Additionally, response to colchicine in HA20 is less frequent than in BD [92]. Thus, it is of importance to recognize clinical characteristics of uveitis in a tertiary center for uveitis in China. Curr eye Res. 2005;30:943–5.

**CONCLUSIONS AND FUTURE DIRECTIONS**

Recent advances in molecular methods and genetic research methodology has greatly expanded our knowledge about the genetic basis of uveitis. Multiple studies have identified that genetic variants were associated with uveitis through influencing the expression of genes or the functions of gene products. These findings also have shed light on the disease mechanisms and clinical translational applications. Despite all these advances, research in this area is still facing considerable challenges.

A major reason is that uveitis is a diverse group of heterogeneous diseases characterized by different clinical findings involving both ocular and extracocular sites. Therefore, for most forms of uveitis the sample sizes studied to date by GWAS have been small enough to robustly identify major genetic effects. Consequently, identified uveitis-related loci only account for a small fraction of the genetic basis of uveitis, indicating most of the causal genes of uveitis have yet to be discovered.

Another approach which has proven productive in other Mendelian randomisation (MR) studies is to investigate shared associations between diseases, traits and other measures, using GWAS data from disease studies to investigate potential causative relationships between diseases, traits and other measures, including epigenetic, immunological, proteomic and transcriptomic data [97, 98]. Very few studies in uveitis genetics have employed this approach, despite in some diseases sufficiently large datasets being available to employ it. This would seem a potentially valuable avenue for future research in this field.

Ultimately though, much larger sample sizes need to be studied to properly dissect the genetics of these conditions. Given the huge unmet need for therapies for these vision- and in some cases life-threatening diseases, international collaboration to achieve the requisite sample sizes appears called for. With genotyping costs having now fallen to quite low levels, the limiting factor in performing these studies is case recruitment. Given that most of these diseases are managed in specialist units in major hospitals, this is surely surmountable. If sufficiently large case cohorts are recruited for genetic studies, the record so far both in immune-mediated diseases overall, and in uveitis itself, shows that it is likely that information gleaned from these hypothesis-free studies will provide valuable information about the pathogenesis of these diseases, and point to potential treatments.

**DATA AVAILABILITY**

This article contains no original research data.

**REFERENCES**

1. Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23:705–17.

2. Yang P, Zhang Z, Zhou H, Li B, Huang X, Gao Y, et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr eye Res. 2005;30:943–8.
24. Li Z, Wu X, Leo PJ, De Guzman E, Akkoc N, Breban M, et al. Polygenic Risk Scores
27. Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH.
28. Remmers EF, Cosan F, Pointon JJ, Su Z, Harvey D, Kocahan G, et al. Interaction
14. Derakhshan MH, Dean L, Jones GT, Siebert S, Gaffney K. Predictors of extra-
15. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther.
17. Yang MM, Lai TY, Luk FO, Pang CP. The roles of genetic factors in uveitis and
18. Huang XF, Chi W, Lin D, Dai ML, Wang YL, Yang YM, et al. Association of IL33 and
25. Ohno S, Aoki K, Sugiura S, Nakayama E, Itakura K, Aizawa M. Letter: HL-A5 and
26. Gul A, Ohno S. HLA-B*51 and Behcet Disease. Ocul Immunol In
11. Lan C, Tam PO, Chiang SW, Chan CK, Luk FO, Lee GK, et al. Manganese super-
4. Brewerton DA, Caffrey M, Nicholls A, Walters D, James DC. Acute anterior uveitis
5. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 years
19. Sato H, Nakamura T, Watanabe A, Hayashi K, Usui H, Inada K, et al. Letter: Immunochip
20. Weisz JM, Holland GN, Roer LN, Park MS, Yuge AJ, Moorthy RS, et al. Association
33. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Association
60. Ryan SJ, Maunene AE. Birdshot retinochoroidopathy. Am J Ophthalmol. 2000;120:777–80.
63.
64

55. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens. 2000;56:522–9.

56. Levinson RD, Rajalingam R, Park MS, Reed EF, Gjertson DW, Kappel PJ, et al. Human leukocyte antigen A29 subtypes associated with birdshot chorioretinopathy. Am J Ophthalmol. 2004;138:631–4.

57. Donvito B, Monnet D, Tabary T, Delair E, Vittier M, Revel B, et al. Different HLA class I region complexotypes for HLA-A:29.2 and -A29.1 antigens, identical in birdshot chorioretinopathy patients or healthy individuals. Invest Ophthalmol Vis Sci. 2005;46:3227–32.

58. Minos E, Barry RJ, Southworth S, Folkard A, Murray P, Duker JS, et al. Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment. Orphanet J Rare Dis. 2016;11:61.

59. Donvito B, Monnet D, Tabary T, Delair E, Vittier M, Revel B, et al. A new HLA extended haplotype containing the A*29:10 allele in birdshot chorioretinopathy: susceptibility narrowed to the HLA molecule itself. Invest Ophthalmol Vis Sci. 2010;51:2525–8.

60. Kuiper JJ, Van Setten J, Ripke S, Van TS, Mulder F, Missotten T, et al. A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1. Eur Respir J. 2011;38:1127–35.

61. Hanson AL, Cuddihy T, Haynes K, Loo D, Morton CJ, Oppermann U, et al. Genetic variants in ERAP1 and ERAP2 associated with immune-mediated diseases influence protein expression and the isofrom profile. Arthritis Rheumatol. 2018;70:255–65.

62. Sanz-Bravo A, Martin-Esteban A, Kuiper JJ, Garcia-Peydro M, Barnea E, Admon A, et al. Allele-specific alterations in the peptide under the joint association of HLA-A*29:02 and Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) with Birdshot Chorioretinopathy. Mol Cell Proteom. 2018;17:1564–77.

63. Alvarez-Navarro C, Martin-Esteban A, Barnea E, Admon A, Lopez de Castro JA. Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Polymorphism relevant to inflammatory disease shapes the peptidome of the birdshot chorioretinopathy-associated HLA-A*29:02 antigen. Mol Cell Proteom. MCP. 2015;14:1770–80.

64. Atmaca LS, Atmaca-Sonmez P, Idil A, Kumbasar OO, Celik G. Ocular involvement of sarcoidosis. Ocul Immunol Inflamm. 2017;25:300–8.

65. Levinson RD, Rajalingam R, Park MS, Reed EF, Gjertson DW, Kappel PJ, et al. Familial granulomatous arthritis, iritis, and rash. J Pediatr. 1985;107:689–93.

66. Micolli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29:129–30.

67. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411:599–603.

68. Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Analysis of five candidate inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016;48:510–8.

69. Kanazawa N, Matsuhashi S, Kambe N, Tachibana T, Nagai S, Miyachi Y. Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation. J Investig Dermatol. 2004;122:851–2.

70. Rose CD, Doyle TM, McIlvain-Simpson G, Coffman JE, Rosenbaum JT, Davie MP, et al. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol. 2005;32:373–5.

71. Milman N, Urisin K, Rodevand E, Nielsen FC, Hansen TV. A novel mutation in the NOD2 gene associated with Blau syndrome: a Norwegian family with four affected members. Scand J Rheumatol. 2009;38:190–7.

72. Caso F, Costa L, Rigante D, Vitale A, Cimaz R, Lucherini OM, et al. Caeats and truths in genetic, clinical, autoimmune and autoinflammatory diseases in Blau syndrome and early onset sarcoidosis. Autoimmun Rev. 2014;13:1220–9.

73. Caso F, Galozzi P, Costa L, Sfisso P, Cantarini L, Punzi L. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn’s disease. RMD open. 2015;1:e000097.

74. Li C, Zhang J, Li S, Han T, Kuang W, Zhou Y, et al. Gene mutations and clinical phenotypes in Chinese children with Blau syndrome. Sci China Life Sci. 2017;60:758–62.

75. Matsuda T, Kambe N, Ueki Y, Kanazawa N, Iwaza K, Honda Y, et al. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation. Ann Rheum Dis. 2020;79:1492–9.

76. Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2013;45:1225–30.

77. Aeschlimann FA, Batu ED, Canna SW, Go E, Gul A, Hoffmann P, et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Arthritis Rheum Dis. 2018;77:728–35.

78. Tsuchida N, Kirino Y, Soejima Y, Onodera M, Arai K, Tamura E, et al. Haploinsufficiency of A20 caused by a novel nonsense variant or entire deletion of TNFAIP3 is clinically distinct from Behcet’s disease. Arthritis Res Ther. 2019;21:137.

79. Kone-Paut I, Georgin-Laviallec S, Galeotti C, Rossi-Semerano L, Hentgen V, Savey L, et al. New data in causes of autoinflammatory diseases. J Bone Spine. 2019;86:554–61.

80. Berneau F, Rouviere B, Delluc A, Nau A, Le Berre R, Sarrabay G, et al. Autosomal dominant familial Behcet disease and haploinsufficiency A20: a review of the literature. Autoimmun Rev. 2018;17:809–15.

81. Huang J, Johnson AD, O’Donnell CJ. PRIme: a method for characterization and evaluation of pleotropic regions from multiple genome-wide association studies. Bioinformatics. 2011;27:1201–6.

82. Evans DM, Davie, Smith G. Mendelian randomization: new applications in the common age of hypothesis-free causality. Annu Rev Genomics Hum Genet. 2015;16:327–50.

83. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat Commun. 2018;9:2244.

84. Wu P, Du L, Hou S, Su G, Yang L, Hu J et al. Association of LACC1, CEBPB-PTPN1, and C9orf22 with anterior uveitis in Chinese females. Mol Vis. 2015;67:140–5.

85. Kim HS, Choi D, Lim LL, Allada G, Smith JR, Austin CR, et al. Association of interleukin 23 receptor gene with sarcoidosis. Dis Mark. 2011;31:17–24.

86. Kuroda H, Saigo Y, Fujiuchi S, Takeda H, Ohsaki Y, Hasebe N. Relationship between cytokine single nucleotide polymorphisms and sarcoidosis among Japanese subjects. Sarcoidosis Vasculitis Diffus Lung Dis: Off J WASOG. 2013;30:36–42.

87. Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr. 1985;107:689–93.

88. Caso F, Cortes A, Bethune J, Han B, et al. Analysis of five candidate inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016;48:510–8.

89. Robinson PC, Clausius TA, Cortes A, Martin TM, Evans DM, Leo P, et al. Genetic dissection of acute anterior uveits reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol. 2015;67:140–51.
103. Hu K, Yang P, Jiang Z, Hou S, Du L, Li F. STAT4 polymorphism in a Chinese Han population with Vogt-Koyanagi-Harada syndrome and Behcet’s disease. Hum Immunol. 2010;71:723–6.

104. Xiang Q, Chen L, Fang J, Hou S, Wei L, Bai L, et al. TNF receptor-associated factor 5 gene confers genetic predisposition to acute anterior uveitis and pediatric uveitis. Arthritis Res Ther. 2013;15:R113.

105. Xiang Q, Chen L, Hou S, Fang J, Zhou Y, Bai L, et al. TRAF5 and TRAF3IP2 gene polymorphisms are associated with Behcet's disease and Vogt-Koyanagi-Harada syndrome: a case-control study. PloS One. 2014;9:e84214.

**AUTHOR CONTRIBUTIONS**
HX and MAB each contributed to the concept and writing and editing the manuscript.

**COMPETING INTERESTS**
The authors declare no competing interests.

**ADDITIONAL INFORMATION**
Correspondence and requests for materials should be addressed to Matthew A. Brown.